This marked a significant advance in targeted therapy for prostate cancer patients, particularly those with BRCA1/2 mutations, expanding the clinically available therapeutic options and improving clinical outcomes in these patients [12,13]. This evidence concerns the gene BRCA1 and Familial prostate cancer.